Tone Ikdahl

Lorenskog, Norway

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Feasibility of a physical activity intervention during and shortly after chemotherapy for testicular cancer.

Feasibility of a physical activity intervention during and shortly after chemotherapy for testicular cancer.

Journal: BMC research notes

Published: June 01, 2016

Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer.

Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer.

Journal: Oncotarget

Published: May 20, 2016

TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: a potential novel approach to the treatment of metastatic colorectal cancer.

TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: a potential novel approach to the treatment of metastatic colorectal cancer.

Journal: Oncotarget

Published: April 14, 2016

The Genomic Landscape of Pancreatic and Periampullary Adenocarcinoma.

The Genomic Landscape of Pancreatic and Periampullary Adenocarcinoma.

Journal: Cancer research

Published: March 11, 2016

Survival-associated heterogeneity of marker-defined perivascular cells in colorectal cancer.

Survival-associated heterogeneity of marker-defined perivascular cells in colorectal cancer.

Journal: Oncotarget

Published: December 23, 2015

Comparing two classifications of cancer cachexia and their association with survival in patients with unresected pancreatic cancer.

Comparing two classifications of cancer cachexia and their association with survival in patients with unresected pancreatic cancer.

Journal: Nutrition and cancer

Published: February 25, 2015

AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin.

AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin.

Journal: The pharmacogenomics journal

Published: January 07, 2015

Molecular signatures of mRNAs and miRNAs as prognostic biomarkers in pancreatobiliary and intestinal types of periampullary adenocarcinomas.

Molecular signatures of mRNAs and miRNAs as prognostic biomarkers in pancreatobiliary and intestinal types of periampullary adenocarcinomas.

Journal: Molecular oncology

Published: June 24, 2014

FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab.

FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab.

Journal: BMC cancer

Published: January 06, 2014

Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity.

Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: November 14, 2013

Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: RESULTS from the NORDIC VII Study.

Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: RESULTS from the NORDIC VII Study.

Journal: PloS one

Published: September 25, 2013

Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment.

Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment.

Journal: Molecular oncology

Published: May 29, 2013

Showing 1-12 of 18

Last Updated: 09/26/2026